Abivax S.A.
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $179.28 | $195.54 | $167.44 | $187.10 | 6.61M |
| Jul 2, 2026 | $186.32 | $194.31 | $176.14 | $179.28 | 2.74M |
| Jul 1, 2026 | $184.56 | $188.53 | $178.11 | $186.32 | 4.44M |
| Jun 30, 2026 | $192.57 | $195.39 | $181.23 | $184.56 | 6.31M |
| Jun 29, 2026 | $196.57 | $205.79 | $186.69 | $192.57 | 5.92M |
| Jun 28, 2026 | $205.37 | $212.14 | $187.53 | $196.57 | 2.78M |
| Jun 27, 2026 | $210.34 | $219.66 | $198.49 | $205.37 | 2.79M |
| Jun 26, 2026 | $206.23 | $213.23 | $199.90 | $210.34 | 5.39M |
Company Overview
Abivax S.A. operates in the consumer staples space within the Consumer Staples sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 10 · Independent 9 of 10| Date | Firm | Target | Rating |
|---|---|---|---|
| Jul 2 | KeyBanc | $207.06 | Hold |
| Jun 27 | Truist Financial | $169.12 | Overweight |
| Jun 13 | Wedbush | $216.75 | Reduce |
| May 16 | Piper Sandler | $237.85 | Neutral |
| May 14 | Needham | $212.20 | Overweight |
| May 7 | Wedbush | $278.64 | Neutral |
Politician Trades
View allWhat's Happening Right Now
- Jun 2, 2026 · Safety ↗ — Abivax shares fell about 32% after cancer concerns overshadowed otherwise positive ulcerative colitis drug efficacy data.
- Jul 1, 2026 · Data Update ↗ — The company presented ABTECT Maintenance Part 2 results and updated obefazimod safety and efficacy data in ulcerative colitis.
- Dec 11, 2025 · Analyst ↗ — A 'Strong Buy' call cited new obefazimod UC data with additional maintenance results anticipated in Q2 2026.
- Nov 8, 2025 · M&A ↗ — Analysts flagged Abivax as a top potential M&A target for 2026 following what was called a 'home run' Phase 3 data readout.
Snapshot
Abivax S.A. (AAVXF) has no Form 10-K on file, so no revenue, profit, or balance-sheet figures are available for this analysis. The company's news flow centers entirely on clinical development of its lead candidate obefazimod in ulcerative colitis, including Phase 3 and maintenance-study data updates. There is no disclosed financial information regarding cash position, spending, or funding runway in the material provided. Investment interest appears to be driven by clinical trial outcomes and takeover speculation rather than reported financial performance.
Bottom Line
Abivax is a clinical-stage biotech whose valuation hinges entirely on obefazimod's ulcerative colitis trial outcomes, with no financial statements available to assess balance-sheet strength or cash runway. Recent data has been a source of both bullish "M&A target" and "Strong Buy" commentary as well as a sharp ~32% share drop tied to cancer safety concerns, underscoring binary, event-driven risk. Investors are effectively betting on clinical and regulatory catalysts rather than any disclosed fundamentals.